Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 51, Issue 3, Pages 397-400Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.109.072819
Keywords
glioblastoma; intracavitary treatment; Y-90-DOTATOC
Ask authors/readers for more resources
The treatment of patients with high-grade malignant glioma still represents an unsolved clinical problem. We report the treatment of 3 patients who had World Health Organization grade IV recurrent glioblastoma: a 23-y-old woman and 2 men aged 61 and 62 y. Methods: All 3 patients were treated with the somatostatin receptor radiopharmaceutical Y-90-labeled [1,4,7,10-tetraazacyclododecane-N, N', N '', N'''-tetraacetic acid(0)-D-Phe(1),Tyr(3)]octreotide (DOTATOC). A cumulated dose of 1.7-2.2 GBq given in 3 or 4 cycles was locally injected into a previously implanted catheter system. Results: Treatment was successful in all 3 patients, with only minor side effects reported. After treatment, MRI and PET showed complete remission in one patient and partial remission in the other patients. These findings correlated well with clinical improvement and improved quality of life. Conclusion: Receptor-mediated radionuclide therapy by locally injected Y-90-DOTATOC is feasible and well tolerated. This approach represents an attractive strategy for the treatment of locally recurring or progressing glioblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available